
pmid: 16456763
Adult, Aged, 80 and over, Male, Clinical Trials as Topic, Carcinoma, Hepatocellular, Dose-Response Relationship, Drug, Maximum Tolerated Dose, Liver Neoplasms, Administration, Oral, Middle Aged, Drug Administration Schedule, Erlotinib Hydrochloride, Confidence Intervals, Humans, Female, Neoplasm Invasiveness, Aged, Follow-Up Studies, Neoplasm Staging, Probability
Adult, Aged, 80 and over, Male, Clinical Trials as Topic, Carcinoma, Hepatocellular, Dose-Response Relationship, Drug, Maximum Tolerated Dose, Liver Neoplasms, Administration, Oral, Middle Aged, Drug Administration Schedule, Erlotinib Hydrochloride, Confidence Intervals, Humans, Female, Neoplasm Invasiveness, Aged, Follow-Up Studies, Neoplasm Staging, Probability
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 2 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
